Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

MVI-118

Vaccine (DNA plasmid) · Immune activation, directed at androgen receptor ligand-binding domain (AR)

Phase 1/2 Most advanced trial
1 Registered trials

What is MVI-118?

MVI-118 is a plasmid DNA vaccine encoding the androgen receptor ligand-binding domain. It stimulates cytotoxic T-lymphocyte responses against AR-expressing prostate cancer cells. The vaccine is studied in prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
pTVG-AR
Drug type
Vaccine (DNA plasmid)
Targets
androgen receptor ligand-binding domain (AR) (antigen)
Mechanism
Immune activation, directed at androgen receptor ligand-binding domain (AR)
Pathways
immune activation, CTL response
Therapy area
Oncology
In trials of
BMY
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
MDW64NA2UY

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04989946 Phase 1/2 Prostate Cancer Active not recruiting BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Prostate Cancer

Other drugs acting on AR

Testosterone FDA approved Bavdegalutamide Phase 1/2 DITEST Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.